Global Scleroderma Initiative

Global Scleroderma Initiative

Scleroderma Research Foundation

Scleroderma Research Foundation

Scleroderma Foundation

Scleroderma Foundation

Federation of European Scleroderma Associations (FESCA)

FESCA

Wednesday, December 23, 2015

FDA approves new orphan drug...

FDA approves new orphan drug to treat pulmonary arterial hypertension.




On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.

Click here for more